Next Article in Journal
Ubiquitin-Specific Protease 21 Promotes Colorectal Cancer Metastasis by Acting as a Fra-1 Deubiquitinase
Previous Article in Journal
The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer
Open AccessArticle

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)

1
Division of Hematology/Oncology, Louisiana State University Health Science Center, New Orleans, LA 70112, USA
2
Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
3
Ochsner Medical Center-Kenner, Neuroendocrine Tumor Clinic, Kenner, LA 70065, USA
4
Department of Epidemiology and Biostatistics, University of Memphis School of Public Health, Memphis, TN 20910, USA
5
Ochsner Medical Center, Department of Internal Medicine, Division of Hematology/Oncology, New Orleans, LA 70122, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 206; https://doi.org/10.3390/cancers12010206
Received: 10 December 2019 / Revised: 3 January 2020 / Accepted: 11 January 2020 / Published: 14 January 2020
Capecitabine and temozolomide (CAPTEM) have shown promising results in the treatment of neuroendocrine neoplasms (NEN). The aim of this study was to evaluate the outcome and role for CAPTEM in malignant neuroendocrine neoplasms. Data were obtained from NEN patients who received at least one cycle of CAPTEM between November 2010 and June 2018. The average number of cycles was 9.5. For analysis, 116 patients were included, of which 105 patients (91%) underwent prior treatment. Median progression free survival (PFS) and overall survival (OS) were 13 and 38 months, respectively. Overall response rate (ORR) was 21%. Disease control rate (DCR) was 73% in all patients. PFS, median OS, ORR, and DCR for pancreatic NENs (pNEN) vs. non-pNEN was 29 vs. 11 months, 35 vs. 38 months, 38% vs. 9%, and 77% vs. 71%, respectively. Patients with pNEN had a 50% lower hazard of disease progression compared to those with non-pNEN (adjusted Hazard Ratio: 0.498, p = 0.0100). A significant difference in PFS was found between Ki-67 < 3%, Ki-67 3–20%, Ki-67 > 20–54%, and Ki-67 ≥ 55% (29 vs. 12 vs. 7 vs. 5 months; p = 0.0287). Adverse events occurred in 74 patients (64%). Our results indicate that CAPTEM is associated with encouraging PFS, OS, and ORR data in patients with NENs. View Full-Text
Keywords: Capecitabine; chemotherapy; neuroendocrine neoplasms; temozolomide Capecitabine; chemotherapy; neuroendocrine neoplasms; temozolomide
Show Figures

Figure 1

MDPI and ACS Style

Thomas, K.; Voros, B.A.; Meadows-Taylor, M.; Smeltzer, M.P.; Griffin, R.; Boudreaux, J.P.; Thiagarajan, R.; Woltering, E.A.; Ramirez, R.A. Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs). Cancers 2020, 12, 206.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop